Drug-drug interactions with tyrosine-kinase inhibitors

Affiliations

¹ Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht 6229 HX, Netherlands; CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands.
² Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht 6229 HX, Netherlands; CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands; Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. Electronic address: frank.de.vries@mumc.nl.

Comment

Sander Croes et al. Lancet Oncol. 2014 Sep.

. 2014 Sep;15(10):e416.

doi: 10.1016/S1470-2045(14)70187-1.

¹ Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht 6229 HX, Netherlands; CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands.
² Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht 6229 HX, Netherlands; CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, Netherlands; Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands. Electronic address: frank.de.vries@mumc.nl.

No abstract available

Comment on

Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. van Leeuwen RW, et al. Lancet Oncol. 2014 Jul;15(8):e315-26. doi: 10.1016/S1470-2045(13)70579-5. Lancet Oncol. 2014. PMID: 24988935 Review.